Lung cancer

ATLANTIC trial shows immune checkpoint inhibitors may have role in advanced NSCLC

The immune checkpoint inhibitor durvalumab may have a role in the treatment of EGFR+ tumours with high PD-L1 expression, results from the phase 2 ATLANTIC study show. Published this week in Lancet Oncology the open-label, single-arm trial involved 444 patients with heavily pre-treated advanced non-small cell lung cancer (NSCLC) from 139 study centres in Asia, Europe, ...

Already a member?

Login to keep reading.

© 2021 the limbic